Care of immunocompromised patients with head and neck cancer during the COVID-19 pandemic: Two challenging and informative clinical cases.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 32298006.
- Also identified by DOI 10.1002/hed.26165 and PMC identifier 7262192.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There is an added level of complexity in the management of head and neck cancer patients with underlying immunosuppressive disorders during the COVID-19 pandemic. Head and neck oncologists are tasked with balancing the dual risks of cancer progression in the setting of impaired tumor immunity and increased susceptibility to life-threatening complications from exposure to viral infection for patients and providers. Through two cases of immunocompromised patients with newly diagnosed head and neck malignancies, we aim to provide guidance to clinicians struggling with how to best counsel and manage this unique subset of patients under these difficult circumstances. After careful consideration of the options, we took different approaches in the care of these two patients. Ultimately, there is no uniform set of rules to apply to this heterogeneous group of immunocompromised patients. We provide some general principles to help guide patient management during the current pandemic.
Medical subject headings
- Conservative Treatment
- Coronavirus Infections
- Head and Neck Neoplasms
- Immunocompromised Host
- Pandemics
- Pneumonia, Viral
- Time-to-Treatment